Detalhe da pesquisa
1.
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV Clin Trials
; 13(4): 228-32, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22849964
2.
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clin Infect Dis
; 53(8): 807-16, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21921224
3.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20074791
4.
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
Hum Vaccin
; 7(9): 919-28, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21860256
5.
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
J Acquir Immune Defic Syndr
; 63(1): 77-85, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23412015